A Retrospective Observational Study of Anlotinib in Patients with Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer

References

• BrayF, FerlayJ, SoerjomataramI, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.2149230207593
   PubMed Web of Science ®Google Scholar
• SiegelRL, MillerKD, JemalA. Cancer statistics, 2018[J]. CA Cancer J Clin. 2018;68(1):7–30.29313949
   PubMed Web of Science ®Google Scholar
• OzolsRF. Systemic therapy for ovarian cancer: current status and new treatments[J]. Semin Oncol. 2006;33(2 Suppl 6):S3–S11.
   Web of Science ®Google Scholar
• Pujade-LauraineE, CombeP. Recurrent ovarian cancer[J]. Ann Oncol. 2016;27(Suppl 1):i63–i65.27141075
   PubMed Web of Science ®Google Scholar
• MonkBJ, MinionLE, ColemanRL. Anti-angiogenic agents in ovarian cancer: past, present, and future[J]. Ann Oncol. 2016;27(Suppl 1):i33–i39.27141068
   PubMed Web of Science ®Google Scholar
• Pujade-LauraineE, HilpertF, WeberB, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized Phase III trial[J]. J Clin Oncol. 2014;32(13):1302–1308.24637997
   PubMed Web of Science ®Google Scholar
• LedermannJA, HackshawA, KayeS, et al. Randomized Phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer[J]. J Clin Oncol. 2011;29(28):3798–3804.21859991
   PubMed Web of Science ®Google Scholar
• BoisA, KristensenG, Ray-CoquardI, et al. Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled Phase 3 trial[J]. Lancet Oncol. 2016;17(1):78–89.26590673
   PubMed Web of Science ®Google Scholar
• J WK, MahnerS, L YW, et al. Pazopanib Maintenance Therapy in East Asian Women With Advanced Epithelial Ovarian Cancer: results From AGO-OVAR16 and an East Asian Study[J]. Int J Gynecol Cancer. 2018;28(1):2–10.26588236
   PubMed Web of Science ®Google Scholar
• C YL, WangY, XiongY, et al. Apatinib combined with oral etoposide in patients with platinum-resistant or platinum-refractory ovarian cancer (AEROC): a Phase 2, single-arm, prospective study[J]. Lancet Oncol. 2018;19(9):1239–1246.30082170
   PubMed Web of Science ®Google Scholar
• NagaoS, KogikuA, SuzukiK, et al. A phase II study of the combination chemotherapy of bevacizumab and gemcitabine in women with platinum-resistant recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer[J]. J Ovarian Res. 2020;13(1):14.32028974
   PubMed Web of Science ®Google Scholar
• McgonigleKF, MuntzHG, VukyJ, et al. Combined weekly topotecan and biweekly bevacizumab in women with platinum-resistant ovarian, peritoneal, or fallopian tube cancer: results of a phase 2 study[J]. Cancer. 2011;117(16):3731–3740.21815133
   PubMed Web of Science ®Google Scholar
• Garcia-MartinezE, RedondoA, PiulatsJM, et al. Are antiangiogenics a good ‘partner’ for immunotherapy in ovarian cancer?[J]. Angiogenesis. 2020.
   Web of Science ®Google Scholar
• SyedYY. Anlotinib: first Global Approval[J]. Drugs. 2018;78(10):1057–1062.29943374
   PubMed Web of Science ®Google Scholar
• YangQ, NiL, ImaniS, et al. Anlotinib Suppresses Colorectal Cancer Proliferation and Angiogenesis via Inhibition of AKT/ERK Signaling Cascade[J]. Cancer Manag Res. 2020;12:4937–4948.32606981
   PubMed Web of Science ®Google Scholar
• LinB, SongX, YangD, et al. Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFRbeta and FGFR1[J]. Gene. 2018;654:77–86.29454091
   PubMed Web of Science ®Google Scholar
• SunL, YangM, ZhangX, et al. Anlotinib combined with etoposide for platinum-resistant recurrent ovarian cancer: A case report[J]. Medicine. 2020;99(20):e20053.32443311
   PubMed Web of Science ®Google Scholar
• EisenhauerEA, TherasseP, BogaertsJ, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)[J]. Eur J Cancer. 2009;45(2):228–247.19097774
   PubMed Web of Science ®Google Scholar
• PignataS, LorussoD, ScambiaG, et al. Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial[J]. Lancet Oncol. 2015;16(5):561–568.25882986
   PubMed Web of Science ®Google Scholar
• ElitL, HirteH. Palliative systemic therapy for women with recurrent epithelial ovarian cancer: current options[J]. Onco Targets Ther. 2013;6:107–118.23459506
   PubMed Web of Science ®Google Scholar
• ShojiT, KomiyamaS, KigawaJ, et al. An open-label, randomized, phase II trial evaluating the efficacy and safety of standard of care with or without bevacizumab in platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer patients previously treated with bevacizumab for front-line or platinum-sensitive ovarian cancer: rationale, design, and methods of the Japanese Gynecologic Oncology Group study JGOG3023[J]. BMC Cancer. 2018;18(1):771.30064406
   PubMed Web of Science ®Google Scholar
• ChekerovR, HilpertF, MahnerS, et al. Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer (TRIAS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial[J]. Lancet Oncol. 2018;19(9):1247–1258.30100379
   PubMed Web of Science ®Google Scholar
• GriffithsRW, Y KZ, EvansS, et al. Outcomes after multiple lines of chemotherapy for platinum-resistant epithelial cancers of the ovary, peritoneum, and fallopian tube[J]. Int J Gynecol Cancer. 2011;21(1):58–65.21178570
   PubMed Web of Science ®Google Scholar
• LedermannJ, HarterP, GourleyC, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial[J]. Lancet Oncol. 2014;15(8):852–861.24882434
   PubMed Web of Science ®Google Scholar
• MatulonisUA, PensonRT, DomchekSM, et al. Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety[J]. Ann Oncol. 2016;27(6):1013–1019.26961146
   PubMed Web of Science ®Google Scholar
• AudehMW, CarmichaelJ, R TP, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial[J]. Lancet. 2010;376(9737):245–251.20609468
   PubMed Web of Science ®Google Scholar
• FongPC, YapTA, BossDS, et al. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval[J]. J Clin Oncol. 2010;28(15):2512–2519.20406929
   PubMed Web of Science ®Google Scholar
• CannistraSA, MatulonisUA, PensonRT, et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer[J]. J Clin Oncol. 2007;25(33):5180–5186.18024865
   PubMed Web of Science ®Google Scholar
• NiuJ, KundrandaMN, MarkmanM, et al. Platinum-Gemcitabine-Avastin (PGA) for platinum-resistant/refractory ovarian cancer[J]. Eur J Gynaecol Oncol. 2017;38(1):40–44.29767862
   PubMed Web of Science ®Google Scholar
• VerschraegenCF, CzokS, C YM, et al. Phase II study of bevacizumab with liposomal doxorubicin for patients with platinum- and taxane-resistant ovarian cancer[J]. Ann Oncol. 2012;23(12):3104–3110.22851407
   PubMed Web of Science ®Google Scholar
• TillmannsTD, LoweMP, WalkerMS, et al. Phase II clinical trial of bevacizumab with albumin-bound paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma[J]. Gynecol Oncol. 2013;128(2):221–228.22960352
   PubMed Web of Science ®Google Scholar
• PovedaAM, SelleF, HilpertF, et al. Bevacizumab combined with weekly paclitaxel, pegylated liposomal doxorubicin, or topotecan in platinum-resistant recurrent ovarian cancer: analysis by chemotherapy cohort of the randomized phase iii AURELIA trial[J]. J Clin Oncol. 2015;33(32):3836–3838.26282651
   PubMed Web of Science ®Google Scholar
• RichardsonDL, M WS, R LC, et al. Paclitaxel With and Without Pazopanib for Persistent or Recurrent Ovarian Cancer: A Randomized Clinical Trial[J]. JAMA Oncol. 2018;4(2):196–202.29242937
   PubMed Web of Science ®Google Scholar
• HirteH, LheureuxS, FlemingGF, et al. A phase 2 study of cediranib in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: a trial of the Princess Margaret, Chicago and California Phase II Consortia[J]. Gynecol Oncol. 2015;138(1):55–61.25895616
   PubMed Web of Science ®Google Scholar
• MiaoM, DengG, LuoS, et al. A phase II study of apatinib in patients with recurrent epithelial ovarian cancer[J]. Gynecol Oncol. 2018;148(2):286–290.29248198
   PubMed Web of Science ®Google Scholar
• ZhangJ, LiA, JiangQ, et al. Efficacy And Safety Of Apatinib Treatment In Platinum-Resistant Recurrent Epithelial Ovarian Cancer: A Real World Study[J]. Drug Des Devel Ther. 2019;13:3913–3918.
   PubMed Web of Science ®Google Scholar
• Du BoisA, KristensenG, Ray-CoquardI, et al. Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial[J]. Lancet Oncol. 2016;17(1):78–89.26590673
   PubMed Web of Science ®Google Scholar
• BaumannKH, Du BoisA, MeierW, et al. A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapy[J]. Ann Oncol. 2012;23(9):2265–2271.22377563
   PubMed Web of Science ®Google Scholar
• ZhouAP, BaiY, SongY, et al. Anlotinib Versus Sunitinib as First-Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial[J]. Oncologist. 2019;24(8):e702–e708.30902918
   PubMed Web of Science ®Google Scholar
• VargaA, Piha-PaulS, P AO, et al. Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: analysis of KEYNOTE-028[J]. Gynecol Oncol. 2019;152(2):243–250.30522700
   PubMed Web of Science ®Google Scholar
• MatulonisUA, Shapira-FrommerR, A DS, et al. Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study[J]. Ann Oncol. 2019;30(7):1080–1087.31046082
   PubMed Web of Science ®Google Scholar
• BambergerES, PerrettCW. Angiogenesis in epithelian ovarian cancer[J]. Mol Pathol. 2002;55(6):348–359.12456770
   PubMedGoogle Scholar
• GonzalezH, HagerlingC, WerbZ. Roles of the immune system in cancer: from tumor initiation to metastatic progression[J]. Genes Dev. 2018;32(19–20):1267–1284.30275043
   PubMed Web of Science ®Google Scholar
• FukumuraD, KloepperJ, AmoozgarZ, et al. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges[J]. Nat Rev Clin Oncol. 2018;15(5):325–340.29508855
   PubMed Web of Science ®Google Scholar
• HuangY, GoelS, DudaDG, et al. Vascular normalization as an emerging strategy to enhance cancer immunotherapy[J]. Cancer Res. 2013;73(10):2943–2948.23440426
   PubMed Web of Science ®Google Scholar